カテゴリー： Market Monitor Global, 世界, 医療/バイオ

膀胱がん標的療法の世界市場見通し2023年-2029年

◆英語タイトル：Targeted Therapy for Bladder Cancer Market, Global Outlook and Forecast 2023-2029
	◆商品コード：MMG23LY8696 ◆発行会社（リサーチ会社）：Market Monitor Global ◆発行日：2023年7月 ◆ページ数：67 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後2-3営業日） ◆調査対象地域：グローバル ◆産業分野：医薬品＆ヘルスケア

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,250 ⇒換算￥487,500	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD4,225 ⇒換算￥633,750	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）	USD4,875 ⇒換算￥731,250	見積依頼/購入/質問フォーム

★Market Monitor Globalに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Global Targeted Therapy for Bladder Cancer Market 調査レポートは次の情報を含め、グローバルにおけるの膀胱がん標的療法市場規模と予測を収録しています。・世界の膀胱がん標的療法市場：売上、2018年-2023年、2024年-2029年
・世界の膀胱がん標的療法市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の膀胱がん標的療法市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。アメリカ市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「アテゾリズマブ（テセントリク）」セグメントは今後6年間、000%の年平均成長率で2029年までに000Mドルに成長すると予測されています。

膀胱がん標的療法のグローバル主要企業は、Pfizer、 Merck KGaA、 Roche、 Astellas、 Janssen Biotech、 Bristol-Myers Squibb、 Merck & Co.、 Gilead Sciencesなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

マーケットモニターグローバル社は、膀胱がん標的療法のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別マーケット分析】

世界の膀胱がん標的療法市場：タイプ別、2018年-2023年、2024年-2029年
世界の膀胱がん標的療法市場：タイプ別市場シェア、2022年
・アテゾリズマブ（テセントリク）、アベルマブ（バベンシオ）、エルダフィチニブ（バルバーサ）、その他

世界の膀胱がん標的療法市場：用途別、2018年-2023年、2024年-2029年
世界の膀胱がん標的療法市場：用途別市場シェア、2022年
・病院、小売薬局、その他

世界の膀胱がん標的療法市場：地域・国別、2018年-2023年、2024年-2029年
世界の膀胱がん標的療法市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競争分析】

また、当レポートは主要な参入企業の分析を提供します。
・主要企業における膀胱がん標的療法のグローバル売上、2018年-2023年
・主要企業における膀胱がん標的療法のグローバル売上シェア、2022年
・主要企業における膀胱がん標的療法のグローバル販売量、2018年-2023年
・主要企業における膀胱がん標的療法のグローバル販売量シェア、2022年

さらに、当レポートは主要企業の情報を提示します。
Pfizer、 Merck KGaA、 Roche、 Astellas、 Janssen Biotech、 Bristol-Myers Squibb、 Merck & Co.、 Gilead Sciences

*************************************************************

・調査・分析レポートの概要
膀胱がん標的療法市場の定義
市場セグメント
世界の膀胱がん標的療法市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の膀胱がん標的療法市場規模
世界の膀胱がん標的療法市場規模：2022年 VS 2029年
世界の膀胱がん標的療法市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの膀胱がん標的療法の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の膀胱がん標的療法製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：アテゾリズマブ（テセントリク）、アベルマブ（バベンシオ）、エルダフィチニブ（バルバーサ）、その他
膀胱がん標的療法のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院、小売薬局、その他
膀胱がん標的療法の用途別グローバル売上・予測

・地域別市場分析
地域別膀胱がん標的療法市場規模 2022年と2029年
地域別膀胱がん標的療法売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業の情報（企業概要、事業概要、主要製品、売上、ニュースなど）
Pfizer、 Merck KGaA、 Roche、 Astellas、 Janssen Biotech、 Bristol-Myers Squibb、 Merck & Co.、 Gilead Sciences
...

Bladder cancer is a disease in which malignant (cancer) cells form in the tissues of the bladder. Targeted therapy is a treatment that targets the cancer’s specific genes, proteins, or the tissue environment that contributes to cancer growth and survival. This type of treatment blocks the growth and spread of cancer cells and tries to limit damage to healthy cells.
This report aims to provide a comprehensive presentation of the global market for Targeted Therapy for Bladder Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Targeted Therapy for Bladder Cancer. This report contains market size and forecasts of Targeted Therapy for Bladder Cancer in global, including the following market information:
Global Targeted Therapy for Bladder Cancer Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Targeted Therapy for Bladder Cancer market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Atezolizumab (Tecentriq) Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Targeted Therapy for Bladder Cancer include Pfizer, Merck KGaA, Roche, Astellas, Janssen Biotech, Bristol-Myers Squibb, Merck & Co. and Gilead Sciences, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Targeted Therapy for Bladder Cancer companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Targeted Therapy for Bladder Cancer Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Targeted Therapy for Bladder Cancer Market Segment Percentages, by Type, 2022 (%)
Atezolizumab (Tecentriq)
Avelumab (Bavencio)
Erdafitinib (Balversa)
Other
Global Targeted Therapy for Bladder Cancer Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Targeted Therapy for Bladder Cancer Market Segment Percentages, by Application, 2022 (%)
Hospital
Retail Pharmacy
Other
Global Targeted Therapy for Bladder Cancer Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Targeted Therapy for Bladder Cancer Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Targeted Therapy for Bladder Cancer revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Targeted Therapy for Bladder Cancer revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
Merck KGaA
Roche
Astellas
Janssen Biotech
Bristol-Myers Squibb
Merck & Co.
Gilead Sciences
Outline of Major Chapters:
Chapter 1: Introduces the definition of Targeted Therapy for Bladder Cancer, market overview.
Chapter 2: Global Targeted Therapy for Bladder Cancer market size in revenue.
Chapter 3: Detailed analysis of Targeted Therapy for Bladder Cancer company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Targeted Therapy for Bladder Cancer in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Targeted Therapy for Bladder Cancer Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Targeted Therapy for Bladder Cancer Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Targeted Therapy for Bladder Cancer Overall Market Size
2.1 Global Targeted Therapy for Bladder Cancer Market Size: 2022 VS 2029
2.2 Global Targeted Therapy for Bladder Cancer Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Targeted Therapy for Bladder Cancer Players in Global Market
3.2 Top Global Targeted Therapy for Bladder Cancer Companies Ranked by Revenue
3.3 Global Targeted Therapy for Bladder Cancer Revenue by Companies
3.4 Top 3 and Top 5 Targeted Therapy for Bladder Cancer Companies in Global Market, by Revenue in 2022
3.5 Global Companies Targeted Therapy for Bladder Cancer Product Type
3.6 Tier 1, Tier 2 and Tier 3 Targeted Therapy for Bladder Cancer Players in Global Market
3.6.1 List of Global Tier 1 Targeted Therapy for Bladder Cancer Companies
3.6.2 List of Global Tier 2 and Tier 3 Targeted Therapy for Bladder Cancer Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Targeted Therapy for Bladder Cancer Market Size Markets, 2022 & 2029
4.1.2 Atezolizumab (Tecentriq)
4.1.3 Avelumab (Bavencio)
4.1.4 Erdafitinib (Balversa)
4.1.5 Other
4.2 By Type – Global Targeted Therapy for Bladder Cancer Revenue & Forecasts
4.2.1 By Type – Global Targeted Therapy for Bladder Cancer Revenue, 2018-2023
4.2.2 By Type – Global Targeted Therapy for Bladder Cancer Revenue, 2024-2029
4.2.3 By Type – Global Targeted Therapy for Bladder Cancer Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Targeted Therapy for Bladder Cancer Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Retail Pharmacy
5.1.4 Other
5.2 By Application – Global Targeted Therapy for Bladder Cancer Revenue & Forecasts
5.2.1 By Application – Global Targeted Therapy for Bladder Cancer Revenue, 2018-2023
5.2.2 By Application – Global Targeted Therapy for Bladder Cancer Revenue, 2024-2029
5.2.3 By Application – Global Targeted Therapy for Bladder Cancer Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Targeted Therapy for Bladder Cancer Market Size, 2022 & 2029
6.2 By Region – Global Targeted Therapy for Bladder Cancer Revenue & Forecasts
6.2.1 By Region – Global Targeted Therapy for Bladder Cancer Revenue, 2018-2023
6.2.2 By Region – Global Targeted Therapy for Bladder Cancer Revenue, 2024-2029
6.2.3 By Region – Global Targeted Therapy for Bladder Cancer Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Targeted Therapy for Bladder Cancer Revenue, 2018-2029
6.3.2 US Targeted Therapy for Bladder Cancer Market Size, 2018-2029
6.3.3 Canada Targeted Therapy for Bladder Cancer Market Size, 2018-2029
6.3.4 Mexico Targeted Therapy for Bladder Cancer Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Targeted Therapy for Bladder Cancer Revenue, 2018-2029
6.4.2 Germany Targeted Therapy for Bladder Cancer Market Size, 2018-2029
6.4.3 France Targeted Therapy for Bladder Cancer Market Size, 2018-2029
6.4.4 U.K. Targeted Therapy for Bladder Cancer Market Size, 2018-2029
6.4.5 Italy Targeted Therapy for Bladder Cancer Market Size, 2018-2029
6.4.6 Russia Targeted Therapy for Bladder Cancer Market Size, 2018-2029
6.4.7 Nordic Countries Targeted Therapy for Bladder Cancer Market Size, 2018-2029
6.4.8 Benelux Targeted Therapy for Bladder Cancer Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Targeted Therapy for Bladder Cancer Revenue, 2018-2029
6.5.2 China Targeted Therapy for Bladder Cancer Market Size, 2018-2029
6.5.3 Japan Targeted Therapy for Bladder Cancer Market Size, 2018-2029
6.5.4 South Korea Targeted Therapy for Bladder Cancer Market Size, 2018-2029
6.5.5 Southeast Asia Targeted Therapy for Bladder Cancer Market Size, 2018-2029
6.5.6 India Targeted Therapy for Bladder Cancer Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Targeted Therapy for Bladder Cancer Revenue, 2018-2029
6.6.2 Brazil Targeted Therapy for Bladder Cancer Market Size, 2018-2029
6.6.3 Argentina Targeted Therapy for Bladder Cancer Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Targeted Therapy for Bladder Cancer Revenue, 2018-2029
6.7.2 Turkey Targeted Therapy for Bladder Cancer Market Size, 2018-2029
6.7.3 Israel Targeted Therapy for Bladder Cancer Market Size, 2018-2029
6.7.4 Saudi Arabia Targeted Therapy for Bladder Cancer Market Size, 2018-2029
6.7.5 UAE Targeted Therapy for Bladder Cancer Market Size, 2018-2029
7 Targeted Therapy for Bladder Cancer Companies Profiles
7.1 Pfizer
7.1.1 Pfizer Company Summary
7.1.2 Pfizer Business Overview
7.1.3 Pfizer Targeted Therapy for Bladder Cancer Major Product Offerings
7.1.4 Pfizer Targeted Therapy for Bladder Cancer Revenue in Global Market (2018-2023)
7.1.5 Pfizer Key News & Latest Developments
7.2 Merck KGaA
7.2.1 Merck KGaA Company Summary
7.2.2 Merck KGaA Business Overview
7.2.3 Merck KGaA Targeted Therapy for Bladder Cancer Major Product Offerings
7.2.4 Merck KGaA Targeted Therapy for Bladder Cancer Revenue in Global Market (2018-2023)
7.2.5 Merck KGaA Key News & Latest Developments
7.3 Roche
7.3.1 Roche Company Summary
7.3.2 Roche Business Overview
7.3.3 Roche Targeted Therapy for Bladder Cancer Major Product Offerings
7.3.4 Roche Targeted Therapy for Bladder Cancer Revenue in Global Market (2018-2023)
7.3.5 Roche Key News & Latest Developments
7.4 Astellas
7.4.1 Astellas Company Summary
7.4.2 Astellas Business Overview
7.4.3 Astellas Targeted Therapy for Bladder Cancer Major Product Offerings
7.4.4 Astellas Targeted Therapy for Bladder Cancer Revenue in Global Market (2018-2023)
7.4.5 Astellas Key News & Latest Developments
7.5 Janssen Biotech
7.5.1 Janssen Biotech Company Summary
7.5.2 Janssen Biotech Business Overview
7.5.3 Janssen Biotech Targeted Therapy for Bladder Cancer Major Product Offerings
7.5.4 Janssen Biotech Targeted Therapy for Bladder Cancer Revenue in Global Market (2018-2023)
7.5.5 Janssen Biotech Key News & Latest Developments
7.6 Bristol-Myers Squibb
7.6.1 Bristol-Myers Squibb Company Summary
7.6.2 Bristol-Myers Squibb Business Overview
7.6.3 Bristol-Myers Squibb Targeted Therapy for Bladder Cancer Major Product Offerings
7.6.4 Bristol-Myers Squibb Targeted Therapy for Bladder Cancer Revenue in Global Market (2018-2023)
7.6.5 Bristol-Myers Squibb Key News & Latest Developments
7.7 Merck & Co.
7.7.1 Merck & Co. Company Summary
7.7.2 Merck & Co. Business Overview
7.7.3 Merck & Co. Targeted Therapy for Bladder Cancer Major Product Offerings
7.7.4 Merck & Co. Targeted Therapy for Bladder Cancer Revenue in Global Market (2018-2023)
7.7.5 Merck & Co. Key News & Latest Developments
7.8 Gilead Sciences
7.8.1 Gilead Sciences Company Summary
7.8.2 Gilead Sciences Business Overview
7.8.3 Gilead Sciences Targeted Therapy for Bladder Cancer Major Product Offerings
7.8.4 Gilead Sciences Targeted Therapy for Bladder Cancer Revenue in Global Market (2018-2023)
7.8.5 Gilead Sciences Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List of Tables
Table 1. Targeted Therapy for Bladder Cancer Market Opportunities & Trends in Global Market
Table 2. Targeted Therapy for Bladder Cancer Market Drivers in Global Market
Table 3. Targeted Therapy for Bladder Cancer Market Restraints in Global Market
Table 4. Key Players of Targeted Therapy for Bladder Cancer in Global Market
Table 5. Top Targeted Therapy for Bladder Cancer Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Targeted Therapy for Bladder Cancer Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Targeted Therapy for Bladder Cancer Revenue Share by Companies, 2018-2023
Table 8. Global Companies Targeted Therapy for Bladder Cancer Product Type
Table 9. List of Global Tier 1 Targeted Therapy for Bladder Cancer Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Targeted Therapy for Bladder Cancer Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Targeted Therapy for Bladder Cancer Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Targeted Therapy for Bladder Cancer Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application – Global Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Targeted Therapy for Bladder Cancer Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Targeted Therapy for Bladder Cancer Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region – Global Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Targeted Therapy for Bladder Cancer Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Targeted Therapy for Bladder Cancer Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2024-2029
Table 30. Pfizer Company Summary
Table 31. Pfizer Targeted Therapy for Bladder Cancer Product Offerings
Table 32. Pfizer Targeted Therapy for Bladder Cancer Revenue (US$, Mn) & (2018-2023)
Table 33. Pfizer Key News & Latest Developments
Table 34. Merck KGaA Company Summary
Table 35. Merck KGaA Targeted Therapy for Bladder Cancer Product Offerings
Table 36. Merck KGaA Targeted Therapy for Bladder Cancer Revenue (US$, Mn) & (2018-2023)
Table 37. Merck KGaA Key News & Latest Developments
Table 38. Roche Company Summary
Table 39. Roche Targeted Therapy for Bladder Cancer Product Offerings
Table 40. Roche Targeted Therapy for Bladder Cancer Revenue (US$, Mn) & (2018-2023)
Table 41. Roche Key News & Latest Developments
Table 42. Astellas Company Summary
Table 43. Astellas Targeted Therapy for Bladder Cancer Product Offerings
Table 44. Astellas Targeted Therapy for Bladder Cancer Revenue (US$, Mn) & (2018-2023)
Table 45. Astellas Key News & Latest Developments
Table 46. Janssen Biotech Company Summary
Table 47. Janssen Biotech Targeted Therapy for Bladder Cancer Product Offerings
Table 48. Janssen Biotech Targeted Therapy for Bladder Cancer Revenue (US$, Mn) & (2018-2023)
Table 49. Janssen Biotech Key News & Latest Developments
Table 50. Bristol-Myers Squibb Company Summary
Table 51. Bristol-Myers Squibb Targeted Therapy for Bladder Cancer Product Offerings
Table 52. Bristol-Myers Squibb Targeted Therapy for Bladder Cancer Revenue (US$, Mn) & (2018-2023)
Table 53. Bristol-Myers Squibb Key News & Latest Developments
Table 54. Merck & Co. Company Summary
Table 55. Merck & Co. Targeted Therapy for Bladder Cancer Product Offerings
Table 56. Merck & Co. Targeted Therapy for Bladder Cancer Revenue (US$, Mn) & (2018-2023)
Table 57. Merck & Co. Key News & Latest Developments
Table 58. Gilead Sciences Company Summary
Table 59. Gilead Sciences Targeted Therapy for Bladder Cancer Product Offerings
Table 60. Gilead Sciences Targeted Therapy for Bladder Cancer Revenue (US$, Mn) & (2018-2023)
Table 61. Gilead Sciences Key News & Latest Developments
List of Figures
Figure 1. Targeted Therapy for Bladder Cancer Segment by Type in 2022
Figure 2. Targeted Therapy for Bladder Cancer Segment by Application in 2022
Figure 3. Global Targeted Therapy for Bladder Cancer Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Targeted Therapy for Bladder Cancer Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Targeted Therapy for Bladder Cancer Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Targeted Therapy for Bladder Cancer Revenue in 2022
Figure 8. By Type - Global Targeted Therapy for Bladder Cancer Revenue Market Share, 2018-2029
Figure 9. By Application - Global Targeted Therapy for Bladder Cancer Revenue Market Share, 2018-2029
Figure 10. By Type - Global Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Targeted Therapy for Bladder Cancer Revenue Market Share, 2018-2029
Figure 12. By Application - Global Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Targeted Therapy for Bladder Cancer Revenue Market Share, 2018-2029
Figure 14. By Region - Global Targeted Therapy for Bladder Cancer Revenue Market Share, 2018-2029
Figure 15. By Country - North America Targeted Therapy for Bladder Cancer Revenue Market Share, 2018-2029
Figure 16. US Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Targeted Therapy for Bladder Cancer Revenue Market Share, 2018-2029
Figure 20. Germany Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2029
Figure 21. France Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Targeted Therapy for Bladder Cancer Revenue Market Share, 2018-2029
Figure 28. China Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2029
Figure 32. India Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Targeted Therapy for Bladder Cancer Revenue Market Share, 2018-2029
Figure 34. Brazil Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Targeted Therapy for Bladder Cancer Revenue Market Share, 2018-2029
Figure 37. Turkey Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Targeted Therapy for Bladder Cancer Revenue, (US$, Mn), 2018-2029
Figure 41. Pfizer Targeted Therapy for Bladder Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Merck KGaA Targeted Therapy for Bladder Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Roche Targeted Therapy for Bladder Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Astellas Targeted Therapy for Bladder Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Janssen Biotech Targeted Therapy for Bladder Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Bristol-Myers Squibb Targeted Therapy for Bladder Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Merck & Co. Targeted Therapy for Bladder Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Gilead Sciences Targeted Therapy for Bladder Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 膀胱がん標的療法の世界市場見通し2023年-2029年(Targeted Therapy for Bladder Cancer Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

膀胱がん標的療法の世界市場見通し2023年-2029年

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp